ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.

Quote:

Search for Ticker

Free Membership

Search:

AMLN: Amylin Pharmaceuticals Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

AMYLIN PHARMACEUTICALS INC (NASD)
AMLN	12.44	-0.33	(-2.58%)	Vol. 1,358,722	16:00 ET

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN injection and BYETTA injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over one thousand five hundred employees nationwide.

General Information

AMYLIN PHARMA

9360 Towne Centre Drive San Diego, CA 92121 Phone: 858-552-2200 Fax: 858-552-2212 Web: www.amylin.com Email: IR@amylin.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	01/26/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	12.77
52 Week High	15.69
52 Week Low	5.92
Beta	1.55
20 Day Moving Average	2,635,539.75
Target Price Consensus	13.21

% Price Change
4 Week	-3.19
12 Week	-3.64
YTD	14.65

% Price Change Relative to S&P 500
4 Week	-4.24
12 Week	-9.15
YTD	-5.11

Share Information
Shares Outstanding (millions)	141.18
Market Capitalization (millions)	1,756.23
Short Ratio	3.37
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.25
Current Year EPS Consensus Estimate	-1.21
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	01/26/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	3.20
30 Days Ago	3.22
60 Days Ago	3.20
90 Days Ago	3.20

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	58.70%
vs. Previous Quarter	47.22%

Sales Growth
vs. Previous Year	-3.26%
vs. Previous Quarter:	0.89%

Price Ratios
Price/Book	3.80
Price/Cash Flow	-
Price / Sales	2.15

ROE
09/30/09	-38.84
06/30/09	-47.37
03/31/09	-49.48

ROA
09/30/09	-10.41
06/30/09	-12.63
03/31/09	-13.39

Current Ratio
09/30/09	3.15
06/30/09	3.20
03/31/09	3.41

Quick Ratio
09/30/09	2.77
06/30/09	2.81
03/31/09	2.99

Operating Margin
09/30/09	-21.36
06/30/09	-25.57
03/31/09	-26.83

Net Margin
09/30/09	-29.39
06/30/09	-35.33
03/31/09	-35.09

Pre-Tax Margin
09/30/09	-29.39
06/30/09	-35.33
03/31/09	-35.09

Book Value
09/30/09	3.28
06/30/09	3.33
03/31/09	3.65

Inventory Turnover
09/30/09	0.78
06/30/09	0.79
03/31/09	0.81

Debt-to-Equity
09/30/09	1.80
06/30/09	1.78
03/31/09	1.63

Debt to Capital
09/30/09	64.30
06/30/09	64.01
03/31/09	61.98


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research